Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 544 Next >>

Filter Applied: complications (Click to remove)

Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020

ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014

Ischemic Stroke and ICU Care
Semin Neurol 28:645-656, Llinas, R, 2008

Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024

Tenecteplase Versus Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2): A Randomised, Open Label, Phase 3 Superiority Trial
Lancet 403:2597-2605, Coutts,S.B.,et al, 2024

Perioperative Management of Anticoagulant and Antiplatelet Therapy
NEJM Evid doi:10.1056/EVIDna2200322, Douketis,J.D. & Spyropoulos,A.C., 2023

Perioperative Acute Ischemic Stroke in Patients with Atrial Fibrillation
Ann Neurol 94:321-329, Shu,L.et al, 2023

Endovascular Therapy for Acute Stroke with a Large Ischemic Region
NEJM 386:doi.10.1056/NEJMoa2118191, Yoshimura, S.,et al, 2022

Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021

Duchenne Muscular Dystrophy
BMJ 368:L7012, Fox, H.,et al, 2020

Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020

Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020

Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled Trial
Lancet 394:1713-1723,1687, The CRASH-3 trial collaborators, 2019

Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018

Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018

Management of Anticoagulants in Patients Undergoing Endoscopic Procedure
www.UptoDate.com, Dec, Kamath, P.S., 2018

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017

Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017

Clinical Imaging Factors Associated with Infarct Progression in Patients with Ischemic Stroke During Transfer for Mechanical Thrombectomy
JAMA Neurol 74:1361-1367,1298, Boulouis, G.,et al, 2017

Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015

Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015

Characteristics of Lumbar Disc Herniation with Exacerbation of Presentation Due to Spinal Manipulative Therapy
Medicine 94:e661, Huang, S.L.,et al, 2015

Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015

Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015

Peri-Procedural Management of Patients Taking Oral Anticoagulants
BMJ 351:h2391, Daniels, P.R., 2015

Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Status, Special Situations, and Unmet Needs
Lancet 386:303-310, Verheugt, F.W.A. & Granger, C.B., 2015

Practice Guideline: Idiopathic Normal Pressure Hydrocephalus: Response to Shunting and Predictors of Response
Neurol 85:2063-2071, Halperin, J.J.,et al, 2015

Anesthetic Drugs in Status Epilepticus: Risk or Rescue?
Neurol 82:656-664, Sutter, R.,et al, 2014

Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014

Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:e103-e104, Fox, R.J., 2014

Recommendations for the Management of Cerebral and Cerebellar Infarction with Swelling
Stroke 45:1222-1238, Wijdicks, E.F.M.,et al, 2014

Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014

The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014

Sturge-Weber Syndrome
UptoDate , Nov, Bodensteiner, J.B., 2014

Infections of the Nervous System, (Bacterial, Fungal, Spirochetal, Parasitic) and Sarcoidosis, Subdural Empyema
Adams & Victors Principles of Neurology, Chp 32, pg 711, Ropper, A.H.,et al, 2014

Herpes Simplex Virus Encephalitis:Clinical Manifestations,Diagnosis and Outcome in 106 Adult Patients
J Clin Virol 60:112-118, Sili,U.,et al, 2014

Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013

Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures
NEJM 368:2113-2124, Baron, T.,et al, 2013

Thrombolysis of Basilar Artery Occlusion: Impact of Baseline Ischemia and Time
Ann Neurol 73:688-694, Strbian, D.,et al, 2013

Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013

Sturge-Weber Syndrome
MedLink Neurology, July, Comi, A.M., 2013

Combined Retinal and Cerebral Hyperperfusion Syndrome after Carotid Thromboendarterectomy
Neurol 81:e166-e167, Ketteler, S.,et al, 2013

CNS-Immune Reconstitution Inflammatory Syndrome in the Setting of HIV Infection, Part 1: Overview and Discussion of Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome and Cryptococcal-Immune Reconstitution Inflammatory Syndrome
AJNR 34:1297-1307, Post, M.J.D.,et al, 2013

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012

Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012

Management of Anticoagulation Before and After Elective Surgery
www.uptodate.com Dec. 2012, Lip, G. & Douketis, J., 2012



Showing articles 0 to 50 of 544 Next >>